Detalhe da pesquisa
1.
Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
J Pharmacokinet Pharmacodyn
; 50(1): 45-62, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600109
2.
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Mult Scler
; 27(14): 2240-2253, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33821693
3.
Correction to: Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
J Pharmacokinet Pharmacodyn
; 50(2): 145, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36870006
4.
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
J Pharmacokinet Pharmacodyn
; 44(3): 263-275, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28251386
5.
A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
J Clin Pharmacol
; 62(8): 1030-1046, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285968
6.
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
J Clin Pharmacol
; 61(3): 339-348, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949472
7.
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Lancet Neurol
; 18(6): 549-558, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31122495
8.
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.
J Clin Pharmacol
; 57(8): 1017-1030, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398628
9.
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Neurology
; 89(15): 1584-1593, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916537
10.
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
J Clin Pharmacol
; 56(10): 1254-62, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26835603